Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Cancers|July 2, 2021
Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing-A Prospective Feasibility StudyMarina Berger, Andrea Thueringer, Doritt Franz, et al.
Plos One|October 2, 2018
Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre studyGeorg Richtig, Christoph Hoeller, Martin Wolf, et al.
International Journal of Molecular Sciences|November 13, 2021
MUG Mel3 Cell Lines Reflect Heterogeneity in Melanoma and Represent a Robust Model for Melanoma in PregnancySilke Schrom, Thomas Hebesberger, Stefanie Angela Wallner, et al.
JACC. Cardiooncology|January 13, 2025
Early Change in C-Reactive Protein and Venous Thromboembolism in Patients Treated With Immune Checkpoint InhibitorsFlorian Moik, Jakob M Riedl, Dominik Barth, et al.
Acta Dermato-Venereologica|September 13, 2018
Knowledge and Influence of Predatory Journals in Dermatology: A Pan-Austrian SurveyGeorg Richtig, Markus Richtig, Wolfram Hoetzenecker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study GroupErika Richtig, H Peter Soyer, Martin Posch, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trialMatteo S Carlino, Georgina V Long, Dirk Schadendorf, et al.
Oncotarget|November 5, 2017
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trialSelma Ugurel, Carmen Loquai, Patrick Terheyden, et al.
Nature Medicine|October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-iReinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Melanoma Research|December 13, 2023
Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trialErika Richtig, Van A Nguyen, Peter Koelblinger, et al.
Pageof 8